SGLT2 抑制剂在人类心脏中激活泛酸激酶
Nicholas Forelli1, Deborah Eaton1, Jiten Patel1
1Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
bioRxiv : the preprint server for biology
|August 2, 2024
概括
糖共传输体-2 抑制剂 (SGLT2i) 激活泛酸激酶1 (PANK1),促进协酶A (CoA) 的合成. 这提高了心脏的燃料消耗,解释了SGLT2i在心力衰竭治疗中的好处.
科学领域:
- 生物化学 生物化学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖共传输体-2 抑制剂 (SGLT2i) 在心力衰竭治疗中显示出显著的益处,但它们的机制与SGLT2独立.
- 对于SGLT2i在心力衰竭中的疗效负责的精确药理目标仍然难以捉摸.
研究的目的:
- 调查SGLT2抑制剂在心力衰竭中治疗作用的直接分子标和机制.
- 阐明泛酸激酶1 (PANK1) 在调解SGLT2抑制剂对心血管的益处中的作用.
主要方法:
- 稳定同位素输液研究在人体和ex vivo perfused心脏组织.
- 使用纯化成分和in silico动态建模的生物化学测试.
- 对PANK1调制和SGLT2i治疗的反应中心肌细胞收缩性的评估.
主要成果:
- SGLT2i 直接激活 PANK1,这种酶是从泛多酸盐 (维生素B5) 中启动协酶-A (CoA) 合成的.
- SGLT2i提高了CoA水平,并刺激了人类失败的心脏的整体燃料利用.
- 观察到SGLT2i与PANK1的直接结合,其中的一种机制涉及预防全抑制.
结论:
- SGLT2 抑制剂通过非目标激活 PANK1.1,在心力衰竭中发挥它们的有益作用.
- 这种激活促进了CoA的合成,并改善了心脏能量代谢,为临床结果提供了机制性的解释.
- 向PANK1可能代表心力衰竭管理的新疗法策略.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
G-Protein Gated Ion Channels
4.6K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
4.6K
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
GPCRs Regulate Adenylyl Cylase Activity
5.4K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.4K
cAMP-dependent Protein Kinase Pathways
6.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.2K
ATP Synthase: Mechanism
14.3K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.3K


